Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
DKK 1.45
+DKK 0.00 (+0.00%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-117.61% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 24.7% YoY with margins expanding 86.3pp.
Negative free cash flow of -DKK 4M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 9M
▲ +24.7% YoY
Net Income (TTM)
-DKK 10M
▲ +27.5% YoY
Op. Margin
-117.60%
▲ +86.3pp YoY
ROIC
-41.24%
▲ +18.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-DKK 7M
▲ +65.5% YoY
Op. Cash Flow (TTM)
-DKK 7M
▲ +65.5% YoY
Net Debt
-DKK 22M
Net Cash Position
Cash & Equiv.
DKK 26M
3Y CAGR: -16.3%
Continue Research
ViroGates A/S (VIRO.XCSE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ViroGates A/S scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
ViroGates A/S scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -117.6% operating margin and a -41.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh VIRO.XCSE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.